These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31931457)

  • 1. Rebound of disease activity after fingolimod withdrawal: Immunological and gene expression profiling.
    Sacco R; Emming S; Gobbi C; Zecca C; Monticelli S
    Mult Scler Relat Disord; 2020 May; 40():101927. PubMed ID: 31931457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis.
    Nygaard GO; Torgauten H; Skattebøl L; Høgestøl EA; Sowa P; Myhr KM; Torkildsen Ø; Celius EG
    Mult Scler Relat Disord; 2022 Jun; 62():103812. PubMed ID: 35462167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe fingolimod rebound syndrome after switching to cladribine treatment.
    Coss-Rovirosa F; Salado-Burbano J; Casallas-Vanegas A; Caire-Herrera LE; Gómez-Figueroa E; Flores-Rivera J
    Mult Scler Relat Disord; 2020 May; 40():101938. PubMed ID: 31982666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical activity after fingolimod cessation: disease reactivation or rebound?
    Frau J; Sormani MP; Signori A; Realmuto S; Baroncini D; Annovazzi P; Signoriello E; Maniscalco GT; La Gioia S; Cordioli C; Frigeni B; Rasia S; Fenu G; Grasso R; Sartori A; Lanzillo R; Stromillo ML; Rossi S; Forci B; Cocco E;
    Eur J Neurol; 2018 Oct; 25(10):1270-1275. PubMed ID: 29851435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
    Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
    JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
    Izquierdo G; O'Connor P; Montalban X; von Rosenstiel P; Cremer M; de Vera A; Sfikas N; Francis G; Radue EW; Kappos L
    Mult Scler; 2014 Jun; 20(7):877-81. PubMed ID: 24293455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
    Delgado S; Hernandez J; Tornes L; Rammohan K
    BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination.
    Rolfes L; Pawlitzki M; Pfeuffer S; Thomas C; Schmidt-Chanasit J; Gross CC; Schulte-Mecklenbeck A; Wiendl H; Meuth SG; M Grauer O; Ruck T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Switching therapy from natalizumab to fingolimod: reduction of the washout time?].
    Sánchez-Gundín J; Flor García A; Martí Gil C; Gómez Romero L
    Farm Hosp; 2015 Sep; 39(5):314-5. PubMed ID: 26546944
    [No Abstract]   [Full Text] [Related]  

  • 10. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
    Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA
    J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors.
    Sepúlveda M; Montejo C; Llufriu S; Sola-Valls N; Reyes D; Martinez-Lapiscina EH; Zubizarreta I; Pulido-Valdeolivas I; Martinez-Hernandez E; Ariño H; Baños N; Saiz A; Blanco Y
    Mult Scler Relat Disord; 2020 Feb; 38():101483. PubMed ID: 31734621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy.
    Fujii C; Kondo T; Ochi H; Okada Y; Hashi Y; Adachi T; Shin-Ya M; Matsumoto S; Takahashi R; Nakagawa M; Mizuno T
    Sci Rep; 2016 Oct; 6():35314. PubMed ID: 27752051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of macular edema without discontinuation of fingolimod in a patient with multiple sclerosis: A case report.
    Akiyama H; Suzuki Y; Hara D; Shinohara K; Ogura H; Akamatsu M; Hasegawa Y
    Medicine (Baltimore); 2016 Jul; 95(29):e4180. PubMed ID: 27442641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
    Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
    JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with fingolimod rebound: A single center real-life experience.
    Goncuoglu C; Tuncer A; Bayraktar-Ekincioglu A; Ayvacioglu Cagan C; Acar-Ozen P; Cakan M; Karabulut E; Karabudak R
    Mult Scler Relat Disord; 2021 Nov; 56():103278. PubMed ID: 34655957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from fingolimod to alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis: Α case series.
    Notas K; Papadaki E; Orologas A; Moschou M; Kimiskidis VK
    Mult Scler Relat Disord; 2020 Feb; 38():101517. PubMed ID: 31751858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal.
    Gomez-Mayordomo V; Montero-Escribano P; Matías-Guiu JA; González-García N; Porta-Etessam J; Matías-Guiu J
    J Med Virol; 2021 Jan; 93(1):546-549. PubMed ID: 32644205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis.
    Montalban X; Comi G; Antel J; O'Connor P; de Vera A; Cremer M; Sfikas N; von Rosenstiel P; Kappos L
    J Neurol; 2015 Dec; 262(12):2627-34. PubMed ID: 26338810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.
    Sánchez P; Meca-Lallana V; Vivancos J
    Mult Scler Relat Disord; 2018 Oct; 25():95-98. PubMed ID: 30056362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation.
    Giordana MT; Cavalla P; Uccelli A; Laroni A; Bandini F; Vercellino M; Mancardi G
    Mult Scler; 2018 Jul; 24(8):1133-1137. PubMed ID: 29708466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.